Prophylaxis for venous thromboembolism in general medical patients

Canadian Journal of Hospital Pharmacy

Volumn 58, Issue 5, 2005, Pages 285-290

  Pattar, Rumi ^a   Kanji, Zahra ^a,b   Collins, Mark ^a,b   Boldt, Michael ^a   Mainra, Rajesh ^a  

^a LIONS GATE HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Educational intervention; General medicine; Prophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; AWARENESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; FEMALE; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PROPHYLAXIS; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

EID: 30744462561     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001; 119(1 Suppl):132S-175S.
2. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-9.
3. Samana MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001;119(1 Suppl):64S-94S.
5. Brophy DF, Dougherty JA, Garrelts JC, Parish RC, Rivey MP, Stumpf JL, et al. Venous thromboembolism prevention in acutely ill nonsurgical patients. Ann Pharmacother 2005;39:1318-24.
6. Leizorovciz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Dalteparin reduced venous thromboembolic events without increased bleeding in acutely ill medical patients. Circulation 2004;110:874-9.
7. Cohen AT, Davidson BL, Gallus AS, Lassen AR, Tomkowski W, Turpie AGG, et al. Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment. [abstract 42]. Blood 2003;102:15a.
8. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am J Heart 2003;145:614-21.
9. Lopez L. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism. Pharmacotherapy 2001;21(6 Pt 2):56S-61S.
10. Davidson BL. Applying risk assessment models in non-surgical patients: overview of our clinical experience. Blood Coag Fibrin 1999;10(suppl 2):S85-9.
11. Armstrong EP, Lipsy RJ. Clinical practice guidelines. In: Carter BL, chair, Editorial Board. Pharmacotherapy self-assessment program. 3rd ed. Kansas City (MO): American College of Clinical Pharmacy; 1999. p. 35-61.
12. Enders JM, Burke JM, Dobesh PP. Prevention of venous thromboembolism in acute medical illness. Pharmacotherapy 2002;22(12):1564-78.
13. Stark JE, Kilzer WJ. Venous thromboembolism prophylaxis in hospitalized medical patients. Ann Pharmacother 2004;38:36-40.
14. Stinnent JM, Pendleton R, Skordos L, Wheeler M, Rodgers GM. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005;78(3):167-72.
15. Rahim SA, Panju A, Pai M, Ginsberg J. Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res 2003;111:215-9.